Beyondspring宣布了评估派姆单抗+普那布林和多西他赛治疗转移性非小细胞肺癌患者的II期303研究的最新疗效和安全性数据;看到了有意义的临床益处

2026-06-02 19:15

Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors
Durable survival benefit: 12-month OS rate of 78.1% and 24-month OS rate of 58.0% in a patient population with limited treatment options
Good tolerability and immune activation: Along with increased frequencies of activated CD4+/CD8+ T cells post-treatment, hematology test also showed safety benefit with significantly higher levels of WBCs, neutrophils and platelets.